Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ESMO Conference | MRG003 NPC Clinical Data Release
抗EGFR单克隆抗体-连接子-强效的微管抑制剂单甲基auristatin E 维贝柯妥塔单抗 MRG003 ADC价格-丁香通
实体瘤新药MRG003最新数据出炉：疾病控制率达66.7%-印塔健康官网
从PD-1单抗到EGFR ADC，乐普生物又带来了什么惊喜？医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
CSCO 2022丨徐瑞华教授团队：突破性疗法！EGFR靶向ADC MRG003治疗晚期鼻咽癌Ⅱ期研究公布 - 肿瘤瞭望
Frontiers | Antibody-drug conjugates: the clinical development in ...
becotatug vedotin (MRG003) / Lepu Med
徐瑞華教授：MRG003榮登2021ESMO，有望成為首個EGFR靶向ADC，造福晚期實體瘤患者
ESMO大会丨MRG003 HNSCC临床数据发布
【4040】2024 ASCO | 徐瑞华教授团队：中国方案MRG003联合普特利单抗数据亮眼，EGFR实体瘤去化疗治疗未来可期医药新闻 ...
#esmo2025 Lepu Biopharma disclosed 3 clinical trials data, including (1 ...
肺癌、鼻咽癌、头颈鳞癌新希望！ADC药物MRG003上市，疗效数据惊艳，疾病控制率高达93.3%
乐普生物全球首创EGFR ADC药物临床试验数据亮眼，MRG003上市申请获NMPA优先受理_摩熵医药
MRG003成药几乎成为必然，或将成为国内首个获批的EGFR ADC_财富号_东方财富网
Becotatug vedotin, MRG003, in previously treated recurrent or ...
《JAMA肿瘤学》：中山大学团队开展的新型EGFR抗体偶联药物临床研究初战告捷！_腾讯新闻
声明 | 东曜药业关于客户乐普生物MRG003新药上市申请的说明医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
手握新型ADC、TCE多抗的天命Biotech
图6 普特利单抗联合MRG003安全性信息
EGFR靶向ADC药物MRG003，或将造福头颈部肿瘤患者_治疗_研究_实体
Becotatug vedotin (MRG003) | Anti-EGFR-ADC | MedChemExpress
疗效翻倍！ADC药物MRG003为经治失败的鼻咽癌患者带来新曙光，生存期延长！
A systematic review of antibody-drug conjugates and bispecific ...
乐普生物：EGFR ADC闪耀ASCO，鼻咽癌注册性临床研究数据以LBA形式公布 Armstrong 2025年5月31日， 乐普生物 ...
MRG003-005试验设计 - 2024年04月 - 行业研究数据 - 小牛行研
HX008MRG003-C001I期临床试验的疗效数据 - 2024年12月 - 行业研究数据 - 小牛行研
微信图片_20250922182845_98_125.png
ESMO 2023临床数据读出，乐普生物MRG003 有望成为鼻咽癌、头颈鳞癌后线治疗金标准 #ADC药物# #乐普生物# #创新药时代来临 ...
圈子
未完待续：乐普生物ADC药物全梳理 - 知乎
EGFR下一站：双抗与ADC医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor ...
中国首个！乐普生物「EGFR ADC」申报上市
HX008/MRG003-C001联合用药的试验设计 - 行业研究数据 - 小牛行研
A Look into Antibody–drug conjugates (ADCs) Targets.pdf
Structural elucidation of antibody drug conjugates (ADCs) using the IgG ...
ESMO 2023临床数据读出，乐普生物MRG003 有望成为鼻咽癌、头颈鳞癌后线治疗金标准-股票频道-和讯网
ESMO大会丨MRG003 NPC临床数据发布
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies ...
Antibody-drug Conjugate Information | ADCdb
2024 ESMO ASIA丨MRG003+普特利单抗II期临床研究成果获口头报告医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
ADC新药MRG003获批，鼻咽癌患者迎来希望 - 知乎
2025年10月30日国家药监局批准全球首款EGFR ADC药物注射用维贝柯妥塔单抗(美佑恒、MRG003、Becotatugvedotin ...
Innovation in Chemistry, Manufacturing, and Controls—A Regulatory ...
Figure 2 from Advances in Antibody–Drug Conjugate Design: Current ...
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or ...
860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for ...
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based ...
国内首个靶向EGFR的ADC药物MRG003拟纳入优先审评，用于鼻咽癌
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to ...
乐普生物：PD-1+EGFR ADC启动鼻咽癌三期临床
国内首款！乐普「EGFR ADC」申报上市，针对鼻咽癌 9月25日，CDE官网显示， 乐普生物 的 EGFR ADC 维贝柯妥塔单抗 ...
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
Antibody–Antibiotic Conjugates: A Novel Therapeutic Platform against ...
Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices
認識表皮生長因子受體（EGFR）之ADC藥物-Becotatug vedotin（MRG003） - 陳駿逸醫師 與你癌歸於好
Molecular glue meets antibody: next-generation antibody–drug conjugates ...
A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and ...
MRG003提交NDA，有望成为我国首个获批鼻咽癌后线治疗的ADC药物 #乐普生物# 9月25日， 乐普生物 MRG003治疗复发/转移性 ...
Characterization of Antibody–Drug Conjugate Pharmacokinetics and in ...
Exploring the Potential of Antibody–Drug Conjugates | Technology Networks
Merck Collaborates with Mersana Developing Novel Immunostimulatory ...
徐瑞华教授牵头，顶级期刊助阵 | EGFR靶向ADC药物MRG003，或将造福头颈部肿瘤患者
Antibody–drug conjugates: Recent advances in payloads - PMC
Structure of antibody–drug conjugates that have reach clinical trials ...
Antibody–Drug Conjugates: The Last Decade
Antibody–Drug Conjugate to Treat Meningiomas
Antibody–drug conjugates for cancer therapy - The Lancet Oncology
Trends in Translational Medicine and Drug Targeting and Delivery: New ...
胰腺癌流行病学特点 - 2024年12月 - 行业研究数据 - 小牛行研
Antibody-drug conjugate Patent Grant Hu October 6, 2 [SHANGHAI ...
维贝柯妥塔单抗（MRG003）拟纳入突破性治疗
Antibody Drug Conjugates as Cancer Therapeutics
Figure 1 from Metabolic engineering of monoclonal antibody ...
Antibody Conjugates-Recent Advances and Future Innovations
ADC药物MRG003（注射用维贝柯妥塔单抗）获批上市，鼻咽癌患者获益
Antibody–Drug Conjugates—A Tutorial Review
ESMO 2023临床数据读出，乐普生物MRG003 有望成为鼻咽癌、头颈鳞癌后线治疗金标准_财富号_东方财富网
.png)
.png)
.png)
.png)
